Company
CNSX:MVMD
Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCMKTS:MVMD) is building a world-class biotech and life sciences company centered around the implementation of its patented Quicksome oral drug formulation and delivery technologies. The company applies its Quicksome desiccation technology towards the oral delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep and anxiety. It is also looking at the fight against the coronavirus (COVID-19). Quicksome enables unprecedented delivery impact through sublingual and buccal formats that provide direct absorption into the bloodstream, dramatically improving drug efficacy, dosing and end-user experience. The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy. The Quicksome technology has been in development since 2010, and initially incorporated into several commercial dietary supplement products. To date, the company has 14 patents in its portfolio, 12 extensions and has filed over a dozen provisional patents with respect to its Quicksome technology.
42 stories · page 3 of 3
To support the accelerated patent examination request, the company said it has provided the patent office with new formulation analyses of different diluted concentrations of its Quicksol Ivermectin in solution
CEO Dennis Hancock said that while making presentations over the past few weeks the firm identified strategic biotech and pharma investors and brought some "significant partners into the fold"
